{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:47:24Z","timestamp":1759333644748},"reference-count":11,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T00:00:00Z","timestamp":1134086400000},"content-version":"vor","delay-in-days":4574,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[1993,6]]},"abstract":"Abstract<\/jats:title>Objective.<\/jats:italic> To examine elevations in levels of serum glutamic oxaloacetic transaminase (SGOT) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) taking placebo, aspirin, or diclofenac, and to seek possible explanations for the occurrence of these elevations.<\/jats:p>Methods.<\/jats:italic> We conducted a metaanalysis of individual case reports from 3 RA protocols and 5 OA protocols, encompassing 814 diclofenac\u2010treated patients, 443 aspirin\u2010treated patients, and 359 placebotreated patients. All of the RA protocols had nearly identical inclusion and exclusion criteria, as well as safety studies and followup; the same was true for the OA protocols. Analysis included correlation analysis and multiple linear and logistic regression, accounting for numerous potential confounding variables, with the SGOT as the dependent variable. F tests were used for hypothesis testing.<\/jats:p>Results.<\/jats:italic> By several analytic approaches, the principal determinants of SGOT concentrations were found to be baseline SGOT value, the use of aspirin in RA patients, and the use of diclofenac in OA patients. Other significant factors contributing to an increase in SGOT concentrations were duration of therapy and, perhaps, daily dosage (mg\/Ib). Hypothesis testing supported these results. Given a statistically average patient, we predicted a 1\u20132% chance of a mildly elevated SGOT level occurring among placebo\u2010treated patients, a 6\u20137% chance among diclofenac\u2010 or aspirin\u2010treated patients with RA, a 12% chance among diclofenac\u2010treated patients with OA, and a 2% chance among aspirin\u2010treated patients with OA.<\/jats:p>Conclusion.<\/jats:italic> This study demonstrates a powerful method for performing metaanalysis, using available individual patient data to examine numerous factors that may affect an outcome of interest. In this case, mild elevations of SGOT were examined and found to be related to baseline SGOT levels, diclofenac use (in OA), and aspirin use (in RA). Of numerous other potential factors examined, including age, sex, alcohol use, concomitant medications, and concomitant diagnoses, only duration of therapy and, to a small extent, daily dosage, were also consistent determinants of SGOT elevation. The SGOT elevations were minimal and were not related to the occurrence of clinical hepatitis: No clinical hepatitis occurred.<\/jats:p>","DOI":"10.1002\/art.1780360610","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T00:39:58Z","timestamp":1171499998000},"page":"804-810","source":"Crossref","is-referenced-by-count":8,"title":["Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis"],"prefix":"10.1002","volume":"36","author":[{"given":"Daniel E.","family":"Furst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,9]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Aspirin and other nonsteroidal antiinflammatory drugs, Arthritis and Allied Conditions","author":"Furst DE","year":"1989"},{"key":"e_1_2_1_3_2","volume-title":"General characteristics of nonsteroidal antiinflammatory drugs, Drugs for Rheumatic Diseases","author":"Schlegel SI","year":"1987"},{"key":"e_1_2_1_4_2","volume-title":"Toxicity of currently used antiinflammatory and anti\u2010rheumatic drugs, Non\u2010Steroidal Anti\u2010Inflammatory Drugs","author":"Rainsford KD","year":"1987"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-95-6-711"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780190205"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90237-1"},{"key":"e_1_2_1_8_2","first-page":"348","article-title":"Naproxen tolerability in the elderly: a summary report","volume":"14","author":"Geczy M","year":"1987","journal-title":"J Rheumatol"},{"key":"e_1_2_1_9_2","first-page":"175","article-title":"1958 revision of diagnostic criteria for rheumatoid arthritis","volume":"9","author":"Ropes MW","year":"1958","journal-title":"Bull Rheum Dis"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"e_1_2_1_11_2","volume-title":"SAS System for Linear Models","year":"1986"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3174-0"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780360610","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780360610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T04:39:38Z","timestamp":1700714378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780360610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1993,6]]}},"alternative-id":["10.1002\/art.1780360610"],"URL":"https:\/\/doi.org\/10.1002\/art.1780360610","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,6]]}}}